{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEK",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK",
    "indicator": {
      "slug": "sales-growth-in-swiss-francs",
      "name": "Sales growth in Swiss francs",
      "definition": "Percentage change in sales reported in Swiss francs over the specified period."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "APAC",
      "name": "Asia-Pacific",
      "type": "bloc"
    },
    "period": {
      "start": "2026-01-01",
      "end": "2026-06-30",
      "type": "quarter"
    },
    "value": -12,
    "value_text": "-12%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "Roche",
      "org_short_name": "Roche",
      "org_url": "https://www.roche.com",
      "org_tier": 2,
      "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...",
      "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23",
      "document_type": "press_release",
      "locator": "Group results",
      "quote": "Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region.",
      "published_date": "2026-07-23",
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK",
      "bibtex": "@misc{roche2026salesbjmgek,\n  author       = {{Roche}},\n  title        = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEK},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}